| abstract |
Pharmaceutically acceptable salts of 3-(4-bromo-2.6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide are disclosed. Specifically the hydrobromide, hemi-citrate, acetate, p-tosylate, L-tartrate and hemi-succinate salts of the abovementioned compound. The compounds disclosed are proposed to treating hyperproliferative diseases, namely cancers of various types. |